In This Article:
Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the next five years to bolster the company's presence in the country.
The commitment includes 15 research and development (R&D) and 13 manufacturing sites across its pharmaceutical and diagnostics divisions.
The investment is projected to generate more than 12,000 new employment opportunities, encompassing around 6,500 jobs in construction and 1,000 in the company's latest and expanded facilities.
According to Roche, the expansion will enhance its current workforce of over 25,000 employees across 24 sites in eight states.
The investment will focus on several key areas, comprising enhancement and upgrading of manufacturing and distribution offerings in the US for the company’s medicines and diagnostics portfolio in California, Indiana, Kentucky, New Jersey and Oregon.
A gene therapy manufacturing facility is to be established in Pennsylvania, along with a new 900,000ft² manufacturing centre, which the company stated will support its burgeoning weight loss medications portfolio, with the location yet to be disclosed.
Indiana will be home to a new manufacturing facility dedicated to continuous glucose monitoring.
Furthermore, Massachusetts will host a new R&D centre specialising in AI research, which will also function as a hub for Roche’s cardiovascular, renal, and metabolism research and development initiatives.
In addition, the company announced that expansions and upgrades are planned for its current pharmaceuticals and diagnostics R&D centres in California, Arizona and Indiana.
Roche anticipates exporting more medicines from the US than it imports, once the new and expanded manufacturing capacities are operational.
Currently, the diagnostics division maintains an export surplus from the country to other nations.
Roche Group CEO Thomas Schinecker said: “Today’s announced investments underscore our long-standing commitment to research, development, and manufacturing in the US.”
Before this development, Roche gained European Commission approval for Columvi (glofitamab) in conjunction with gemcitabine and oxaliplatin (GemOx) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
"Roche announces $50bn US investment in pharma and diagnostics" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.